Aligos Q3 net loss $33.1M ($0.78 loss per share); clinical programs advance

Aligos Therapeutics, Inc.

2022-Q3 EPS reported -$2.31

Net loss $33.1M, EPS $(0.78) vs net loss $33.3M, EPS $(11.00) in Q3 2020.
R&D expenses $28.1M (up from $17.3M) on continued development of three CHB candidates and NASH drug.
Cash, cash equivalents and investments $242.7M as of Sep 30, 2021, down slightly from $243.5M.
Dosing of ASO candidate ALG-020572 in healthy volunteers started; STOPS cohorts (120, 200 mg) fully enrolled.
CTA filed for NASH candidate ALG-055009 (THR-β agonist); dosing in healthy volunteers expected Q4 2021.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.